WTNH

Bracco Diagnostics Inc. Obtains Hallmark Achievement of One Million Injections with its MRI agent VUEWAY® (gadopiclenol) solution for injection

PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...
Monthly Prescribing Reference

Novel GBCAs Elucirem, Vueway Now Available for Use in Contrast Enhanced MRI

Gadopiclenol only requires half of the gadolinium dose of conventional nonspecific GBCAs. Elucirem ™ (gadopiclenol) and Vueway ™ (gadopiclenol) are now available for use with magnetic resonance ...
WHNT

Cision PR Newswire

PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...
WCBD

Preeminent Hospitals and Medical Practices Nationwide Lead in Patient Care with First Use of Bracco's VUEWAY™ (gadopiclenol) solution for injection for MRI

Requiring half the gadolinium dosage compared to other macrocyclic gadolinium-based contrast agents (GBCAs) in approved indications in the U.S., gadopiclenol also has the highest relaxivity compared ...
WDAF-TV

American College of Radiology Classifies VUEWAY® as a Group II Agent Relative to NSF

The ACR Committee on Drugs and Contrast Media states that, "Gadopiclenol demonstrates kinetic stability and a long dissociation half-life that is comparable to other Group II macrocyclic agents," and ...
PR Newswire

The CHMP adopted a positive opinion for Vueway® (gadopiclenol) for its use in pediatric patients under 2 years of age

MILAN, Dec. 19, 2025 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces that on 11 December 2025 the Committee for Medicinal Products for Human Use (CHMP) of the ...
KXAN

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY ...

VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use i VUEWAY injection is approved for use in adult and pediatric ...
WGNO

The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union

Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), ...
Finanznachrichten

Bracco Group: The CHMP adopted a positive opinion for Vueway (gadopiclenol) for its use in pediatric patients under 2 years of age

The benefit-risk ratio of Vueway considered positive in children from birth MILAN, Dec. 19, 2025 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces that on 11 ...